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Transplantation of mesenchymal stromal cells (MSCs) to sites of experimentally created 
nerve injury in laboratory animals has shown promising results in restoring nerve function. 
This approach for nerve regeneration has not been reported in horses. In this study, we 
first evaluated the in vitro ability of equine bone marrow-derived MSCs (EBM-MSCs) to 
trans-differentiate into Schwann-like cells and subsequently tested the MSCs in vivo for 
their potential to regenerate a transected nerve after implantation. The EBM-MSCs from 
three equine donors were differentiated into SCLs for 7 days, in vitro, in the presence of 
specialized differentiation medium and evaluated for morphological characteristics, by 
using confocal microscopy, and for protein characteristics, by using selected Schwann 
cell markers (GFAP and S100b). The EBM-MSCs were then implanted into the fascia sur-
rounding the ramus communicans of one fore limb of three healthy horses after a portion 
of this nerve was excised. The excised portion of the nerve was examined histologically 
at the time of transection, and stumps of the nerve were examined histologically at day 
45 after transplantation. The EBM-MSCs from all donors demonstrated morphological 
and protein characteristics of those of Schwann cells 7 days after differentiation. Nerves 
implanted with EBM-MSCs after nerve transection did not show evidence of nerve 
regeneration at day 45. Examination of peripheral nerves collected 45 days after injury 
and stem cell treatment revealed no histological differences between nerves treated with 
MSCs and those treated with isotonic saline solution (controls). The optimal delivery of 
MSCs and the model suitable to study the efficacy of MSCs in nerve regeneration should 
be investigated.
Keywords: horse, nerve regeneration, peripheral nerve, stem cells, mesenchymal stromal cells, neuropathies
Abbreviations: EBM-MSCs, equine bone marrow-derived mesenchymal stromal cells; GFAP, glial fibrillary acidic protein; 
MSCs, mesenchymal stromal cells; SLCs, Schwann-like cells.
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inTrODUcTiOn
Horses suffer injury to peripheral nerves from trauma, metabolic 
disease, toxins, genetic disorders, and degenerative and infectious 
diseases (1–3). Sequelae to nerve injury in horses frequently 
include poor performance, disability, or even death, which, in 
turn, result in profound financial and emotional burden.
Schwann cells form the myelin sheath surrounding axons in 
the peripheral nervous system. This sheath is regularly segmented 
by the nodes of Ranvier, which help in transmitting the nerve 
impulse in a saltatory and, thus, extremely fast manner (4). 
Peripheral nerves are able to regenerate after injury due to the 
secretion of cytokines and neurotrophic factors emanating from 
the damaged cells (especially from Schwann cells) and to phago-
cytosis of cellular debris by local macrophages (5–7).
Residual nerve function depends on the magnitude and 
chronicity of damage to the nerve (8). The prognosis for recovery 
of a nerve is poorest when the nerve is transected, and its fibers 
and surrounding fascia (connective tissue) have been completely 
disrupted. This magnitude of damage is known as neurotmesis in 
Seddon’s classification of peripheral nerve injury (9, 10). Surgical 
techniques for repairing nerves involve apposing the stumps 
of the nerve with sutures or inserting a graft to bridge the gap 
between the stumps (5, 6). Some of the most commonly used 
materials for fabricating grafts or scaffolds consist of vein, artery, 
nerve, silicone, collagen, laminin, gels made of platelet-rich 
plasma (PRP), and synthetic polymers (11, 12). Regardless of the 
technique of tissue engineering used, clinical results are often 
disappointing (10, 13).
Results of research using laboratory animals indicate that 
using mesenchymal stromal cells (MSCs) might be an alternative 
approach for repairing nervous tissue, including injury to the 
spinal cord and peripheral nerves (14–16). The neuroprotective 
effects of MSCs have been widely described and involve anti-
inflammatory, immunomodulatory, angiogenic, and nurturing 
mechanisms (17–20). Furthermore, MSCs from bone marrow 
or adipose tissue are able to differentiate into Schwann-like cells 
(SLCs) after being chemically induced under specific conditions 
(16, 21, 22). SLCs transplanted into experimentally created nerv-
ous lesions of laboratory animals have enhanced repair of axons 
and myelin and improved sensory and motor functions, perhaps 
as a consequence of the secretion of specific neurotrophic factors 
that promote nerve repair (15, 16, 20).
There are no reports describing outcomes of horses treated 
for peripheral nerve injury with equine bone marrow-derived 
MSCs (EBM-MSCs) or any report that describes the ability of 
EBM-MSCs to differentiate into myelinated SLCs. These stud-
ies are necessary before EBM-MSCs can be used in veterinary 
medicine to enhance regeneration of damaged peripheral nerves. 
We have recently reported that EBM-MSCs are able to display 
morphological and protein characteristics of neural progenitors 
(23). In this preliminary study, we evaluated the ability of EBM-
MSCs to differentiate into SLCs after chemical induction, in vitro. 
Additionally, we describe a new model of peripheral nerve injury 
in the horse and discuss the outcome after implanting undiffer-
entiated EBM-MSCs into an experimentally created nerve lesion 
in three horses.
MaTerials anD MeThODs
isolation, expansion, and characterization 
of eBM-Mscs
Bone marrow-derived MSCs, obtained from the sternum, 
previously characterized and cryopreserved from three equine 
donors, were assessed for their stem cell properties, as described 
(19). Briefly, all cells were confirmed to be mesenchymal stromal/
stem cells based on their colony-forming unit assays, MTS viabil-
ity and proliferation assays, and the adipogenic, chondrogenic, 
and osteogenic differentiation patterns, as described in previous 
studies (24). Low-passage MSCs (P1 to P4) isolated from three 
equine donors were used in all in vitro experiments described 
below.
Trans-Differentiation of eBM-Mscs into 
schwann-like cells
Low-passage equine MSCs were seeded at a density of 8 to 
10 × 106 cells onto 100 mm Primaria™ nitrogen-coated tissue 
culture dishes (Becton Dickinson Labware, Bedford, MA, USA). 
Cells were maintained in regular growth medium containing 
Dulbecco’s modified Eagle medium/Ham’s F-12 (DMEM-F12) 
(Cellgro™, Manassas, VA, USA), 10% fetal bovine serum (FBS), 
and 1% penicillin/streptomycin, at 37°C and 5% CO2, for 48 h 
to allow attachment. Neural differentiation was induced using 
a previously described method (16). To induce neural dif-
ferentiation, the growth medium was removed, and cells were 
pre-incubated with medium containing DMEM-F12, 20% FBS, 
and 1  mM β-mercaptoethanol (Sigma-Aldrich®, Saint Louis, 
MO, USA), at 37°C and 5% CO2, for 18–24  h. Subsequently, 
the cells were induced by adding neural medium containing 
DMEM-F12, 10% FBS, and 35  ng/mL all-trans-retinoic acid. 
The medium was replaced after 3 days with DMEM-F12, 10% 
FBS, and a mixture of cytokines containing the following 
ingredients: 5 μM forskolin (Sigma-Aldrich®, Saint Louis, MO, 
USA), 200 ng/mL recombinant human heregulin-β1 (HRG-β1) 
(Sigma-Aldrich®, Saint Louis, MO, USA), 5  ng/mL platelet-
derived growth factor (Sigma-Aldrich®, Saint Louis, MO, USA), 
and 10  ng/mL recombinant human basic fibroblast growth 
factor (Sigma-Aldrich®, Saint Louis, MO, USA). The cells were 
incubated in this medium, which was replaced every 72 h, for 
7 days.
For cytoplasmic staining, SLCs and undifferentiated EBM-
MSCs were stained with 5 μg of wheat-germ agglutinin (WGA, 
Alexa Fluor® 488 conjugate) (Life Technologies™, Grand 
Island, NY, USA) for 10 min, at room temperature. To stain the 
nucleus, cells were washed and stained with 5 μg of TO-PRO®-3 
iodide stain (Life Technologies™, Grand Island, NY, USA) 
for 10  min, at room temperature. The cells were washed and 
mounted with Slowfade® Gold antifade reagent (Molecular 
Probes®, Grand Island, NY, USA) and photographed through 
a laser-scanning spectral confocal microscope (Leica TCS SP2) 
(Leica Microsystems©, Wetzlar, Germany), at 20× and 63× 
magnification.
Total cell lysates were prepared from SLCs and undif-
ferentiated EBM-MSCs using 200 μL of RIPA buffer (Boston 
FigUre 1 | equine model of peripheral nerve injury. Dissection (left) and 
transection (right) of the ramus communicans nerve of a fore limb of a horse. 
A 6-mm diameter biopsy punch was used to transect the center of the nerve.
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Bioproducts™, Ashland, MA, USA) and sonicated, and 
supernatants containing total proteins were recovered by cen-
trifugation. Total proteins in each sample were quantitated, and 
concentrations were  determined using BCA assay at 660  nm 
(Pierce®, Thermo Scientific™, Waltham, MA, USA). Equal 
concentrations (20  μg per lane) of total proteins from SLCs 
and undifferentiated MSCs were electrophoretically separated 
in a 12% acrylamide gel and transferred onto nitrocellulose 
membranes. The membranes were blocked with 5% bovine 
serum albumin (BSA) and incubated with mouse anti-S-100b 
(BD Pharmingen™, San Diego, CA, USA) (1:1000), mouse 
anti-β3 tubulin (Santa Cruz Biotechnology™, USA) (1:1000), 
and mouse anti-GFAP (BD Pharmingen™, San Diego, CA, 
USA) (1:1000). Horseradish peroxidase (HRP)-conjugated 
goat anti-mouse IgG (BD Pharmingen™, San Diego, CA, 
USA) (1:5000) was used as the secondary antibody. Antigens 
were detected after being exposed to ECL-2 reagent (Pierce®, 
Thermo Scientific™, Waltham, MA, USA). Beta-actin was used 
as a loading control.
To observe proteins using immunofluorescence, SLCs and 
undifferentiated EBM-MSCs were fixed with 4% paraformalde-
hyde, permeabilized with 0.1% Triton X-100 (Sigma-Aldrich®, 
Saint Louis, MO, USA) for 10  min, at room temperature, and 
blocked with 5% normal serum for 30 min, at room temperature. 
Cells were washed and incubated overnight, at 4°C, with 5 μg 
of primary antibodies against S-100b (BD Pharmingen™, San 
Diego, CA, USA) and GFAP (BD Pharmingen™, San Diego, 
CA, USA). After being washed with HBSS buffer, cells were 
incubated with 5 μg Alexa Fluor® 647 donkey anti-mouse IgG 
(BD Pharmingen™, San Diego, CA, USA), for 20 min, at room 
temperature, mounted with Slowfade® Gold antifade with DAPI 
reagent (Molecular Probes®, Grand Island, NY, USA), and photo-
graphed through a laser-scanning spectral confocal microscope 
(Leica Microsystems©, Wetzlar, Germany).
subjects
Three healthy American Quarter Horse, crossbred mares, 
9–13 years old, from the University of Tennessee’s teaching herd 
were used in the study. All procedures were carried out according 
to a protocol approved by the Institutional Animal Care and Use 
Committee.
equine Model of Peripheral nerve injury
Horses were sedated with detomidine hydrochloride (0.01–
0.02 mg/kg, IV) and butorphanol tartate (0.01–0.02 mg/kg, IV). 
The distal palmar aspect of both metacarpi was prepared for 
aseptic surgery, and 2 mL of 2% mepivacaine hydrochloride was 
deposited subcutaneously adjacent to the medial palmar nerve 
and adjacent to lateral palmar nerve proximal to the palpable 
ramus communicans lying palmar to the superficial digital flexor 
tendon. A scalpel blade was used to create a 15-mm long, cutane-
ous, longitudinal incision over the ramus communicans. Using 
a 6-mm diameter biopsy punch, the center of this anastomotic 
nerve, connecting the medial and lateral palmar nerves, was 
removed and placed in 10% formalin (Figure 1). The same pro-
cedure was performed on the contralateral fore limb.
Treatments and histological  
analysis of nerve Tissue
After excising a portion of the ramus communicans of one ran-
domly selected fore limb, 10 ×  106 allogeneic, undifferentiated 
MSCs (from a mare, whose MSCs had been previously character-
ized), suspended in 1 mL of sterile isotonic saline solution were 
instilled into the fascia surrounding the medial and lateral stumps 
of the ramus communicans (Figure 2). The same volume of sterile 
isotonic saline solution was injected around the stumps of the 
contralateral nerve (control). The cutaneous incision was closed 
with staples, and the distal portion of each fore limb was band-
aged. The horses received phenylbutazone at the time of surgery 
(4.4 mg/kg, PO) and the day after surgery (2.2 mg/kg, PO). The 
limbs were bandaged until the staples were removed on day 14. 
Bandages were changed every third day.
The stumps of ramus communicans of each fore limb of each 
horse (n = 3) were harvested 45 days post stem cell therapy. To 
remove the stumps, the horses were sedated with xylazine hydro-
chloride (0.5 mg/kg, IV) and anesthetized with ketamine hydro-
chloride (2.2 mg/kg, IV). General anesthesia was maintained with 
isofluorane vaporized in oxygen and delivered through a semi-
closed system into a cuffed endotracheal tube inserted orally into 
the trachea. The horses were placed in right lateral recumbency. 
A cutaneous, 2-cm, longitudinal incision was created over the 
medial and lateral aspects of the flexor tendons of both fore limbs 
to expose the medial and lateral stumps of the ramus communi-
cans. The medial and lateral stumps of the nerve were transected 
close to the medial or lateral palmar nerve and placed in Carson’s 
fixative until processed for histological examination. The same 
procedure was performed on the contralateral fore limb, and 
the incisions were closed with staples, and the distal portion of 
each fore limb was bandaged. All horses recovered uneventfully 
from anesthesia. The limbs were bandaged until the staples were 
removed on day 14. Bandages were changed every third day.
FigUre 3 | Wga cytoplasmic and TO-PrO-3-iodide nuclear immunofluorescent stains showing the integrity of eBM-Mscs (left) and slcs (right). 
Note the typical fibroblast-like morphology of the EBM-MSCs (control), the elongation of the SLCs into a spindle shape, the appearance of one or more cellular 
processes, and the growth of cells into a “whorl-like” pattern, at day 7. Scale bar = 100 μm.
FigUre 2 | Transplantation of allogeneic eBM-Mscs into the fascia 
surrounding the ramus communicans of a fore limb of a horse 
following nerve transection.
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Five-micrometer thick sections of Carson’s fixed, paraffin-
embedded nerve excised from the ramus communicans and from 
the stumps of the ramus communicans were examined by light 
microscopy.
resUlTs
No horses showed sign of discomfort or became lame after the 
surgical procedures, and none of the horses exhibited any sign 
of immunological response after allogenic EBM-MSCs were 
implanted in the nerve defects.
schwann cell Differentiation of  
eBM-Mscs In Vitro
The integrity of the nucleus and cytoplasm of the cells was 
examined using fluorescence microscopy. TO-PRO®-3 stain and 
WGA, specific to the cell membrane, were used to demonstrate 
the nucleus and the cytoplasmic structure of the SLCs. Low-
passage EBM-MSCs demonstrated the potential to undergo 
trans-differentiation after being chemically induced for 7  days. 
Trans-differentiation was observed subjectively using morpho-
logical changes in cells exposed to the differentiation medium 
relative to the undifferentiated controls. The cells elongated until 
they displayed spindle-shaped morphology, accompanied by the 
appearance of one or two cell processes (Figure 3). These cells 
grew in a “whorl-like” pattern, a phenotype typical of Schwann 
cells. Cells undergoing differentiation displayed this morphologi-
cal change at 4 days after chemical induction, and approximately 
80% of the cells had acquired this morphologic change by 7 days. 
The undifferentiated controls maintained the typical fibroblastic 
appearance of a MSC throughout the 7-day period. Subjectively, 
no differences were observed in the phenotypic characteristics of 
SLCs, generated from EBM-MSCs, among equine donors.
The expression of S-100b and GFAP was confirmed by a com-
bination of immunofluorescence (Figure  4) and immunoblot 
(Figure 5) analyses. The expression profiles were confirmed in 
SLCs differentiated from the EBM-MSCs of all equine donors. 
Interestingly, immunoblot analyses showed that the undifferenti-
ated control cells expressed β3 and GFAP, but failed to express 
S-100b. Results suggest that β3 and GFAP may be neural progeni-
tor markers, and their expression can be used as an indicator to 
demonstrate plasticity (i.e., the ability of equine MSCs to differ-
entiate into other cellular lineages beyond that of the mesodermal 
lineages).
FigUre 4 | expression of schwann-cell proteins in eBM-Mscs trans-differentiated into schwann-like cells. Confocal microscopy shows the expression 
of S100b (red) and GFAP (green) in Schwann-like cells from a middle-aged horse after 7 days of chemical induction. Scale bar = 100 μm.
FigUre 5 | expression of neural progenitor and schwann-cell 
proteins by immunoblot analysis. Western blot analysis shows the 
expression of the neural progenitor proteins β3 tubulin and GFAP, and the 
expression of the Schwann-cell protein S100b on equine Schwann-like cells 
from middle-aged (lane 1) and young (lane 2) horses. Undifferentiated 
EBM-MSCs show the expression of the neural progenitor proteins β3 tubulin 
and GFAP on cells from middle-aged (lane 3) and young (lane 4) horses. 
Beta-actin was used as an internal control. Twenty micrograms of protein 
was loaded per lane. Note the expression of GFAP on undifferentiated MSCs, 
suggesting that the plasticity of EBM-MSCs may go beyond mesodermal 
lineages. S100b could not be detected by immunoblots. Undifferentiated 
MSCs did not show Schwann-cell protein expression.
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Peripheral nerve regeneration
The microscopic appearance of the nerves in all specimens tran-
sected with the punch biopsy on the first surgical procedure was 
within normal limits. On day 45, all stumps treated with isotonic 
saline solution and all stumps treated with MSCs had seromas 
characterized by cleft-like spaces rimmed by, or partially filled by, 
aggregates of fibrin overlain, bordered, or partially infiltrated by 
fibroblastic cells and macrophages (Figure 6). The isotonic saline-
treated and MSC-treated stumps had formed post-traumatic, 
transectional neuromas characterized by haphazard streams, 
whorls, and fascicles of small vessels, fibroblasts, and Schwann 
cells (Figure  7). No localized or discrete population of MSCs 
or primitive cells (e.g., neural or Schwann-cell progenitors) was 
recognized.
DiscUssiOn
Peripheral nerves can be injured by chemical, thermal, or 
mechanical trauma (25). Direct trauma, metabolic disease, such 
as hypoparathyroidism, electrolyte imbalance, and equine motor 
neuron disease, and idiopathic disease, such as damage to the 
left recurrent laryngeal nerve (recurrent laryngeal neuropathy), 
appear to be the nerve injuries most commonly reported in 
the horse. Treating horses for damage to a peripheral nerve, by 
administering one or more anti-inflammatory drugs and physical 
rehabilitation, is often unrewarding. Repair of transected nerve 
fibers of human beings is enhanced by closing the gap by appos-
ing the nerve endings and their surrounding fascia with sutures 
or by inserting an autograft (11). The use of autografts in horses, 
however, might not be practical and could result in unwanted 
sequelae (26).
Techniques investigated to repair damaged nerves using 
regenerative therapies include transplantation of MSCs, alone 
or in combination with bioengineered materials, for the purpose 
of providing proper environmental conditions for survival 
and proliferation of cells that can aid nerve repair, particularly 
Schwann cells (20, 27). Based on experimental studies in labora-
tory animals, the transplantation of MSCs after peripheral nerve 
injury speeds regain of motor and sensory nerve functions (15, 
20, 28, 29). Additionally, studies have demonstrated that MSCs 
are capable of extra-mesodermal differentiation, including dif-
ferentiation into cells from neural lineage. Transplantation of 
MSCs differentiated into SLCs on to injured nerves has revealed 
promising results on nerve function and morphology (14, 15, 30).
We chemically induced low-passage, bone marrow-derived 
MSCs from young and middle-aged horses to determine their 
plasticity into SLCs. Morphological changes, determined by 
phase-contrast and fluorescence microscopic examinations, 
became evident by 7 days after chemical induction in all horses. 
Differentiated cells were elongated, had an oval-shaped cytoplasm, 
and had formed one or multiple cellular processes. These cells 
appeared to multiply to form patches, whereas undifferentiated 
MSCs multiplied to form flat, even layers.
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Western blot and immunofluorescence analyses revealed the 
expression of the Schwann cell markers S-100b and GFAP in SLCs. 
Undifferentiated MSCs also expressed β3 and GFAP, as previously 
reported by our group (23), but not S-100b. Expression of β3 and 
GFAP suggests that EBM-MSCs are capable of differentiating into 
cells of extra-mesodermal lineages (31).
The in vitro portion of this study relied mainly on morpho-
logical analysis and Schwann-cell protein markers to describe 
the events occurring during differentiation of EBM-MSCs into 
SLCs. Our results were similar to those experiments performed 
using bone marrow-derived MSCs from rats and humans, in 
which cells were able to differentiate and express markers typical 
of Schwann cells (7, 21, 30, 32).
The in vivo portion of this study used a model for acute periph-
eral nerve injury in the horse, which has not previously been 
reported. As opposed to other models of peripheral nerve injury, 
transecting the ramus communicans does not cause sensory or 
functional impairment in the horse. This is an important welfare 
matter. Additionally, we evaluated the effects on speed and pat-
tern of nerve regeneration after transplantation with allogeneic 
MSCs. Transplanting MSCs that had differentiated into SLCs was 
not possible due to poor viability of the differentiated cells (25% 
viable) after the cells were detached from the tissue culture flasks. 
A method to optimize collection of equine SLCs is necessary. 
Furthermore, no histological differences were observed between 
nerve stumps treated with MSCs and those treated with isotonic 
saline solution (controls).
For this specific study, we had previously characterized the 
stemness of the MSCs from all our equine donors. Horses with 
various diseases presented to our institution have been treated 
with allogeneic MSCs previously characterized and stored. We 
have subjectively perceived benefits from transplanting these 
allogeneic cells into damaged tendons and ligaments. Our 
study was aimed at differentiating allogeneic MSCs into SLCs 
for treating horses for nerve injuries because the ultimate aim 
of our research is to have cells readily available to use for regen-
erating damaged nerves, because to regenerate nerves, expedi-
tious treatment after injury is critical for success. Allogeneic 
MSCs can be used as an “off the shelf ” product soon after injury, 
whereas culturing and expanding autogenous MSCs requires 
several days.
Results were inconclusive using our model for acute periph-
eral nerve injury in the horse, perhaps because of the low num-
ber of horses used and perhaps because of other factors, such 
as surgical technique, anatomical region of the experimentally 
injured nerve (the distal aspect of the limb of the horse has less 
FigUre 6 | Formation of seromas at the transection sites. Hematoxylin and eosin staining showed all nerves treated with saline solution (left) and MSCs (right) 
had cleft-like spaces rimmed by or partially filled by aggregates of fibrin overlain or infiltrated by fibroblastic cells and macrophages. 100× magnification.
FigUre 7 | Formation of post-traumatic neuromas on peripheral nerves 45 days after nerve transection. Hematoxylin and eosin staining showed that 
both the isotonic saline solution-treated (left) and the MSCs-treated (right) nerves formed neuromas characterized by haphazard streams, whorls, and fascicles of 
small vessels, fibroblasts, and Schwann cells. No population of MSCs or primitive neural cells was recognized. 100× magnification.
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